Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USANA guidance

This article was originally published in The Tan Sheet

Executive Summary

Firm expects net sales to increase 47% and top $60 mil. in first quarter ending April 3, with earnings per share slightly lower than originally forecast. The Salt Lake City-based firm attributes the earnings decrease to costs and delays in entry into the Mexican market, as well as higher cost of goods sold at Wasatch, Utah facility. USANA projects full-year sales to fall at the high end of $245 to $255 mil. guidance, with EPS between $1.35 and $1.40...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096673

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel